Tissue Factor and Tissue Factor Pathway Inhibitor in Hemodialysis Patients

Yorioka, Noriaki; Taniguchi, Yoshihiko; Yamashita, K.; Ueda, Chiyuki; Nakamura, Chikako; Harada, Satoru; Yamakido, Michio

doi:10.1177/039139889802101118

Cited by 10 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Soejima et al [35] proposed that not only an increase in the plasma levels of TF but also an increase in free TFPI posed the risk of a grim fate for patients with unstable Zemanová /Opatrný Jr/ Opatrná/Vít/Šefrna/Racek angina. In their study, Yorioka et al [36] observed that the TFPI levels in hemodialysis patients with occlusion of vascular access were higher than in patients without occlusion. To be able to propose other hypotheses beyond endothelial injury, plasma TF and TFPI activity measurements are needed.…”

Section: Discussionmentioning

confidence: 89%

Tissue Factor, Its Pathway Inhibitor, and Metabolic Disturbances in Long-Term Peritoneal Dialysis

Zemanová

Opatrný²,

Opatrná³

et al. 2003

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aim: The tissue factor (TF) plays a key role in triggering the coagulation system in vivo. Our study was designed to determine whether or not the plasma levels of TF and its pathway inhibitor (TF pathway inhibitor; TFPI) in patients with chronic renal failure (CRF) treated by peritoneal dialysis (PD) (1) are pathologically altered; (2) differ between diabetics and nondiabetics, and (3) depend on the metabolic disorders associated with CRF and/or diabetes. Methods: Using ELISA, plasma TF and TFPI levels were measured once in 21 PD patients (10 with diabetes, 11 without diabetes) and in 21 healthy subjects. Results: As compared with healthy subjects (TF 282 pg/ml; TFPI 73 ng/ml), both TF and TFPI levels were significantly higher in PD patients with diabetes (485 pg/ml, p < 0.001, and 106 ng/ml, p < 0.01, respectively) and in PD patients without diabetes (480 pg/ml, p < 0,001, and 121 ng/ml, p < 0.001, respectively). The difference between diabetics and nondiabetics was not significant. In stepwise regression analysis, the TF levels depended on serum creatinine (partial correlation 0.39, p < 0.05), glycemia (0.43, p < 0.01), and insulin (–0.43, p < 0.05), and the TFPI levels depended on creatinine (partial correlation 0.67, p < 0.001), apolipoprotein B (0.46, p < 0.01), and plasma fibrinogen (0.43, p < 0.01). Conclusions: CRF patients on PD show increased plasma TF and TFPI levels. There is no difference between diabetics and nondiabetics. The TF and TFPI levels depend significantly on the renal function, as assessed by serum creatinine, and on some metabolic disorders. Elevated TF and TFPI levels may be related to thrombosis and atherosclerosis in CRF patients on PD.

show abstract

Section: Discussionmentioning

confidence: 89%

Tissue Factor, Its Pathway Inhibitor, and Metabolic Disturbances in Long-Term Peritoneal Dialysis

Zemanová

Opatrný²,

Opatrná³

et al. 2003

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

“…described higher levels of tissue factor on monocytes in hemodialysis patients in comparison to healthy controls [14]. Al-Saady et al showed a hypercoagulable state in patients with chronic renal failure as a contributing factor for the increased cardiovascular and cerebrovascular event rate [16].…”

Section: Discussionmentioning

confidence: 99%

“…They are known to modulate both inflammation and thrombosis, which promote the development of clinical atherosclerosis [13]. Tissue factor expression on monocytes is important in extrinsic coagulation and elevated in HD patients compared to healthy controls [14].…”

Section: Introductionmentioning

confidence: 99%

Short- and long-term effects of hemodialysis on platelet and monocyte activity markers of atherosclerosis in patients with end-stage renal disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…One important finding is that the presence of cardiovascular disease is closely linked to the tissue factor system [19]. Yorioka et al described higher levels of tissue factor on monocytes in haemodialysis patients in comparison to a healthy control group [14]. Pawlak et al demonstrated a relationship between increased oxidative stress and elevated tissue factor in peritoneal dialysis patients [20].…”

Section: Discussionmentioning

confidence: 99%

“…Binding of CD40L to its CD40 receptor on endothelial cell membranes induces an enhanced release of potent proinflammatory and atherosclerosis-promoting cytokines and chemokines (e.g., IL-6 and MCP-1) [13]. Tissue factor expression on monocytes is important in extrinsic coagulation and elevated in HD patients compared to that in healthy controls [14]. It is known that a disturbed platelet function is an important cause for thromboembolic and haemorrhagic complications in ESRD patients.…”

Section: Introductionmentioning

confidence: 99%

Elevation of Platelet and Monocyte Activity Markers of Atherosclerosis in Haemodialysis Patients Compared to Peritoneal Dialysis Patients

Stach

Karb

Akın

et al. 2017

Mediators of Inflammation

View full text Add to dashboard Cite

Purpose The predominant cause of mortality in dialysis patients are cardiovascular events. Platelet and monocyte activity markers play an important role in cardiovascular mortality and were assessed and related to dialysis quality criteria in haemodialysis (HD) and peritoneal dialysis (PD) patients. Methods For this prospective comparative study, HD patients (n = 41) and PD patients (n = 10) were included. In whole blood samples, surface expression of CD62P and CD40L on platelets, tissue factor binding on monocytes, and platelet-monocyte aggregates were measured by flow cytometry. Plasma levels of MCP-1, IL-6, TNFα, and soluble CD40L were analysed by enzyme-linked immunosorbent assay. Results Haemodialysis patients showed a significantly higher CD62P expression on platelets (p = 0.017), significantly higher amount of platelet-monocyte aggregates (p < 0.0001), and significantly more tissue factor binding on monocytes (p < 0.0001) compared to PD patients. In PD patients, a significant correlation between Kt/V and platelet CD40L expression (r = 0.867; 0.001) and between Kt/V and platelet CD62P expression (r = 0.686; p = 0.028) was observed, while there was no significant correlation between Kt/V and tissue factor binding on monocytes and platelet-monocyte aggregates, respectively. Conclusion Platelet and monocyte activity markers are higher in HD patients in comparison with those in PD patients, possibly suggesting a higher risk of cardiovascular morbidity and mortality.

show abstract

Tissue Factor and Tissue Factor Pathway Inhibitor in Hemodialysis Patients

Cited by 10 publications

References 12 publications

Tissue Factor, Its Pathway Inhibitor, and Metabolic Disturbances in Long-Term Peritoneal Dialysis

Tissue Factor, Its Pathway Inhibitor, and Metabolic Disturbances in Long-Term Peritoneal Dialysis

Short- and long-term effects of hemodialysis on platelet and monocyte activity markers of atherosclerosis in patients with end-stage renal disease

Elevation of Platelet and Monocyte Activity Markers of Atherosclerosis in Haemodialysis Patients Compared to Peritoneal Dialysis Patients

Contact Info

Product

Resources

About